Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06671886 · ClinicalTrials.gov registry record · NA
NAFLD Clinical Care Pathway
A NA study of NAFLD and MASLD, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- NA
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT06671886: Recruiting NA study of NAFLD and MASLD, sponsored by VA Office of Research and Development.
NCT06671886 is a NA study of NAFLD and MASLD that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 32 participants, below the 164-participant average among 26 other NAFLD trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06671886, a NA study of NAFLD and MASLD, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
Non-alcoholic fatty liver disease (NAFLD) is a new condition that has become the most common chronic liver disease in the world and a main cause of liver cirrhosis, liver failure and liver cancer. Obesity and diabetes, conditions that are very common among Veterans are the main risk factors for NAFLD. Therefore, the burden of NAFLD and its complications among Veterans is substantial. However, most VA patients with NAFLD are undiagnosed and untreated, and their care is not consistent with practice guidelines. The NAFLD Clinical Care Pathway (NCCP) intervention seeks to close this major gap in the care of Veterans by automatically identifying patients at risk of NAFLD, calculating their risk scores of having severe NAFLD, and educating the primary care providers on the diagnosis and treatment of NAFLD. This clinical trial will test the benefit of this NCCP intervention against usual care in increasing the rates of NAFLD diagnosis as well as referral to and enrollment in appropriate treatment. The study will also identify barriers and promotors of future NCCP implementation.
Primary Outcome
The investigators will use chart reviews to extract unstructured data regarding the primary outcome measure: existence of EHR progress note documenting a new NAFLD diagnosis AND complete risk stratification of NAFLD (i.e., fibrosis). The investigators will use our validated process to guide uniform abstraction and classification.
Interventions
- BEHAVIORAL E-trigger
Study Locations (1)
Texas
- Michael E. DeBakey VA Medical Center, Houston, TX - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2024-02-02 |
| Est. Completion | 2028-11-13 |
| Phase | NA |
What NCT06671886 shows while recruiting
NCT06671886 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 164-participant average among 26 other NAFLD trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with NAFLD appearing as the primary indexed condition, and to 1 intervention - of which E-trigger is the first listed.
NCT06671886 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06671886 about?
NCT06671886 is a clinical study titled "NAFLD Clinical Care Pathway". Non-alcoholic fatty liver disease (NAFLD) is a new condition that has become the most common chronic liver disease in the world and a main cause of liver cirrhosis, liver failure and liver cancer. Obesity and diabetes, conditions that are very common among Veterans are the main risk factors for NAFL...
What is the current status of trial NCT06671886?
This trial is currently recruiting. It is a NA study. The enrollment target is 32 participants. The study started on 2024-02-02. Estimated completion is 2028-11-13.
What conditions does trial NCT06671886 study?
This clinical trial studies the following conditions: NAFLD, MASLD.
What interventions are being tested in trial NCT06671886?
The interventions under investigation include: E-trigger (BEHAVIORAL).
Who is sponsoring clinical trial NCT06671886?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06671886 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NAFLD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06671886's enrollment target sits among peer trials
32 23rd of 26 higher than 4 of 26 other NAFLD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NAFLD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reversal of Lipid-Induced Insulin Resistance
RECRUITING · NA
-
NASH AMPK Exercise Dosing (AMPED) Trial
RECRUITING · NA
-
Effect of VLCD on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and NAFLD
ACTIVE NOT RECRUITING · NA
-
An Imaging-based Quantitative Biomarker Assay for NAFLD in Children
ACTIVE NOT RECRUITING · NA
-
The Impact of Low-fat and Full-fat Dairy Consumption on Glucose Homeostasis (DAIRY Study)
COMPLETED · NA
-
Healthy Liver - Healthy Brain
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI